Health and Happiness (H&H) International (1112) Investor Day 2026 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2026 summary
19 May, 2026Strategic partnership and business overview
Highlighted a 15-year strategic partnership with Isigny, emphasizing mutual trust and quality as core to infant nutrition success in China and globally.
Infant milk formula is the second-largest business, representing nearly one-third of total revenue and ranking fifth in China and first in France's pharmacy channel for organic formula.
Isigny partnership is foundational, with H&H holding priority on production volumes and a significant ownership stake.
The partnership supports expansion and resilience, with capacity available for further growth and readiness to invest in new facilities if needed.
Isigny’s cooperative model ensures reinvestment in quality, sustainability, and farmer welfare, aligning with B Corp values.
Financial performance and growth drivers
Group revenue grew 34% year-to-date, with Baby Nutrition up over 60% and infant formula exceeding 72% growth.
Pediatric probiotics and kids nutrition segments returned to strong double-digit growth at 23%.
Adult Nutrition and Care business grew 26% in Q1, with China and Australia both achieving double-digit growth.
Pet nutrition, mainly Zesty Paws in North America, grew 17% and now accounts for 11.6% of group revenue.
Strong cash reserves (2.1 billion RMB) enabled significant deleveraging, reducing gross debt by over 300 million RMB in Q1.
Product innovation and market positioning
Biostime IMF’s growth is driven by high-quality, science-based formula design, including the launch of HMO products with the highest 2'-FL dosage approved in China.
Consumer-centric branding and early-stage recruitment strategies target new generations of mothers.
Normande breed cow milk, unique to the region, offers higher A2 protein and OPO levels, supporting product differentiation.
Manufacturing uses patented spray-drying technology for superior dissolving speed and quality.
The company maintains a focus on natural, terroir-based sourcing rather than genetic modification for A2-only milk.
Latest events from Health and Happiness (H&H) International
- Double-digit revenue and profit growth, lower leverage, and market leadership in key segments.1112
H2 202514 May 2026 - Q1 2026 revenue rose 34.4% with strong growth in nutrition and robust cash flow; outlook positive.1112
Q1 2026 TU24 Apr 2026 - Revenue up 4.9% with strong China growth, higher adjusted net profit, and interim dividend declared.1112
H1 20253 Feb 2026 - Revenue and profit fell as IMF declined, but nutrition supplements and cash flow improved.1112
H1 202423 Jan 2026 - Supplements now drive 67.7% of revenue as IMF falls, with 2025 set for recovery.1112
H2 20247 Jan 2026